Home Drug IndexClinical Monograph

Esomeprazole Uses, Dosage, Side Effects & Price | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Proton Pump Inhibitor (PPI)

Subclass

Substituted benzimidazole derivative

Speciality

Gastroenterology

Schedule (India)

Schedule H

Routes

Oral, Intravenous

Formulations

Form	Strengths
Tablets (enteric-coated/delayed-release)	20 mg, 40 mg
Capsules (delayed-release)	20 mg, 40 mg
Powder for oral suspension (sachets)	10 mg, 20 mg, 40 mg
Injection (lyophilized powder for reconstitution)	40 mg per vial

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Gastroesophageal Reflux Disease (GERD)

A. Non-erosive Reflux Disease (NERD) / Mild-to-Moderate GERD:

Parameter	Details
Starting dose	20 mg orally once daily, taken before breakfast
Titration	Not routinely required
Usual maintenance dose	20 mg once daily
Maximum dose	40 mg once daily
Duration	4 weeks initially; extend to 8 weeks if healing incomplete

B. Erosive Esophagitis:

Parameter	Details
Starting dose	40 mg orally once daily
Titration	Not applicable
Usual maintenance dose	20 mg once daily (after healing)
Maximum dose	40 mg once daily
Duration	4–8 weeks for healing; long-term maintenance at 20 mg if required

Clinical Notes:

Administer at least 30–60 minutes before first meal of the day
Reassess need for continued therapy periodically
Rule out malignancy before initiating long-term therapy in patients with alarm features

2. Peptic Ulcer Disease (Gastric / Duodenal Ulcer)

A. Helicobacter pylori Eradication — Triple Therapy:

Parameter	Details
Starting dose	Esomeprazole 20 mg twice daily
Titration	Not applicable
Usual maintenance dose	20 mg twice daily (as part of regimen)
Maximum dose	20 mg twice daily
Duration	10–14 days

Combination regimen:

Esomeprazole 20 mg BD + Amoxicillin 1 g BD + Clarithromycin 500 mg BD

Clinical Notes:

Verify local clarithromycin resistance patterns before prescribing
Alternative regimens (bismuth-based quadruple therapy, sequential therapy) may be preferred in high-resistance areas

B. NSAID-Associated Ulcer — Treatment:

Parameter	Details
Starting dose	20–40 mg orally once daily
Titration	Not applicable
Usual maintenance dose	20–40 mg once daily
Maximum dose	40 mg once daily
Duration	4–8 weeks

C. NSAID-Associated Ulcer — Prophylaxis:

Parameter	Details
Starting dose	20 mg orally once daily
Titration	Not applicable
Usual maintenance dose	20 mg once daily
Maximum dose	20 mg once daily
Duration	Duration of NSAID therapy in high-risk patients

3. Zollinger-Ellison Syndrome / Pathological Hypersecretory Conditions

Parameter	Details
Starting dose	40 mg orally twice daily
Titration	Individualised based on acid output; may increase in 20 mg increments
Usual maintenance dose	40–80 mg twice daily (divided doses)
Maximum dose	240 mg/day in divided doses
Duration	Long-term; as clinically indicated

Clinical Notes:

Specialist supervision mandatory
Doses above 80 mg/day should be given in divided doses
Periodic assessment of acid output and symptom control

4. Stress Ulcer Prophylaxis (ICU Setting)

Parameter	Details
Starting dose	40 mg IV once daily
Titration	Not applicable
Usual maintenance dose	40 mg IV once daily
Maximum dose	40 mg IV once daily
Duration	Until patient tolerates enteral feeding or ICU discharge

Clinical Notes:

Preferred in patients who are NPO or unable to take oral medications
Transition to oral therapy as soon as feasible
Reserve use for high-risk ICU patients (mechanical ventilation, coagulopathy, severe sepsis)

5. Prevention of Rebleeding After Endoscopic Haemostasis (Peptic Ulcer Bleed)

Parameter	Details
Starting dose	80 mg IV bolus over 30 minutes
Titration	Followed by continuous IV infusion at 8 mg/hour for 72 hours
Usual maintenance dose	After 72 hours: 40 mg orally once daily
Maximum dose	80 mg IV bolus; 8 mg/hour infusion (total ~192 mg in first 24 hours)
Duration	IV for 72 hours, then oral for 4–8 weeks

Clinical Notes:

Indicated following successful endoscopic haemostasis of high-risk ulcer stigmata
Intermittent high-dose IV bolus (e.g., 40 mg IV BD) is an acceptable alternative where continuous infusion is not feasible

Secondary Indications — Adults (Off-label, if any)

Indication	Dose	Duration	Notes
Functional Dyspepsia — OFF-LABEL	20 mg once daily	2–4 weeks trial	Evidence: RCTs and Indian gastroenterology practice support short-term PPI trial for epigastric pain/discomfort unrelated to organic pathology. Reassess if no response.
Barrett's Oesophagus (Maintenance) — OFF-LABEL	40 mg once daily (may use twice daily under specialist guidance)	Long-term	Specialist only. Evidence: Standard of care in gastroenterology practice; aims to control reflux and potentially reduce dysplasia progression. Endoscopic surveillance mandatory.

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

1. GERD / Erosive Oesophagitis — Oral Route

Age: ≥1 year

Weight	Starting Dose	Usual Maintenance	Maximum Dose	Duration
10–19 kg	10 mg once daily	10 mg once daily	10 mg/day	4–8 weeks
20–40 kg	10–20 mg once daily	10–20 mg once daily	20 mg/day	4–8 weeks
>40 kg	20–40 mg once daily	20–40 mg once daily	40 mg/day	4–8 weeks

Clinical Notes:

Administer before meals
Granules/oral suspension may be preferred in younger children unable to swallow capsules
Monitor symptom response, weight gain, and any signs of GI bleeding

2. Erosive Oesophagitis — Intravenous Route (when oral not feasible)

Age: ≥1 month

Parameter	Details
Dose	0.5–1 mg/kg IV once daily
Maximum dose	20 mg/day (for <20 kg); 40 mg/day (for ≥20 kg)
Duration	Until oral route tolerated

Clinical Notes:

Administer IV dose over 10–30 minutes
Convert to oral therapy as soon as clinically feasible

Age Restriction:
Not recommended below 1 month of age except under specialist paediatric gastroenterology supervision with clear clinical indication and risk-benefit assessment.

Secondary Indications — Paediatrics (Off-label, if any)

Indication	Age	Dose	Duration	Notes
H. pylori Eradication — OFF-LABEL	≥6 years	1 mg/kg/dose twice daily (max 20 mg BD) with Amoxicillin + Clarithromycin	10–14 days	Specialist only. Evidence: Extrapolated from adult data and IAP recommendations. Weight-appropriate antibiotic dosing essential.

Safety Monitoring (All Paediatric Patients):

Assess symptom improvement at 4 weeks
Monitor for adverse effects (headache, abdominal pain, diarrhoea)
Periodic reassessment of need for continued therapy
Long-term use: consider monitoring magnesium and B12 if therapy exceeds 12 months

Renal Adjustments

No dose adjustment required in renal impairment (mild, moderate, or severe).

Renal Status	Recommendation
All stages of CKD	No dose adjustment required
Haemodialysis	Esomeprazole is not significantly removed by dialysis; no supplemental dose required
Peritoneal dialysis	No specific data; standard dosing generally acceptable

Note: Use caution with prolonged therapy in severe renal impairment due to limited long-term safety data. Monitor for hypomagnesaemia if on concurrent diuretics.

Hepatic adjustment

Contraindications

Known hypersensitivity to esomeprazole, omeprazole, or other substituted benzimidazole PPIs
Concurrent use with atazanavir (results in significantly reduced atazanavir absorption and loss of antiretroviral efficacy)
Concurrent use with rilpivirine (contraindicated due to substantial reduction in rilpivirine levels)
Concurrent use with nelfinavir

Cautions

Long-term use (>1 year): Risk of vitamin B12 deficiency, hypomagnesaemia, and bone fractures (hip, wrist, spine)
Elderly patients: Higher susceptibility to hypomagnesaemia and fractures
History of osteoporosis or fracture risk factors
History of Clostridioides difficile infection or recent antibiotic use
Chronic liver disease — monitor hepatic function periodically
Risk of masking gastric malignancy: Rule out malignancy (endoscopy recommended) before initiating long-term therapy in patients with alarm symptoms (weight loss, dysphagia, anaemia, haematemesis, persistent vomiting)
Concurrent use of high-dose methotrexate
Patients on clopidogrel — assess risk-benefit

Pregnancy

Parameter	Details
Overall safety	Limited human data; animal studies show no teratogenic effects
Risk category	Considered relatively safe (former FDA Category B equivalent)
Preferred alternatives	Pantoprazole generally preferred in Indian obstetric practice when PPI indicated
When to use	May be used when H2-receptor antagonists or antacids are inadequate and benefit outweighs potential risk
Monitoring	Maternal symptom control; fetal growth assessment if prolonged use

Lactation

Parameter	Details
Compatibility	Compatible with breastfeeding
Milk levels	Low — limited excretion into breast milk
Preferred alternatives	None required; may use standard doses
Infant monitoring	Observe for feeding difficulties, unusual irritability, or diarrhoea (rare); monitor weight gain if mother on prolonged therapy

Elderly

Parameter	Recommendation
Starting dose	Same as adults (20–40 mg once daily depending on indication)
Titration	Not routinely required
Special considerations	Increased risk of hypomagnesaemia (especially with concurrent diuretics), vitamin B12 deficiency, bone fractures (hip, wrist, spine), and Clostridioides difficile infection. Use lowest effective dose for shortest duration. Consider calcium and vitamin D supplementation in those with fracture risk.

Major drug interactions

Interacting Drug	Mechanism / Effect	Recommendation
Atazanavir	Reduced atazanavir absorption due to elevated gastric pH	Contraindicated — avoid combination
Rilpivirine	Substantially reduced rilpivirine levels	Contraindicated — avoid combination
Nelfinavir	Reduced nelfinavir absorption	Contraindicated — avoid combination
Clopidogrel	Esomeprazole inhibits CYP2C19, reducing conversion of clopidogrel to active metabolite	Use with caution; consider alternative PPI (pantoprazole, rabeprazole) if PPI essential in patients on dual antiplatelet therapy
High-dose Methotrexate	PPIs may delay methotrexate clearance, increasing toxicity risk	Temporarily discontinue esomeprazole during high-dose methotrexate cycles

Moderate drug interactions

Interacting Drug	Effect	Recommendation
Warfarin	Possible modest increase in INR	Monitor INR when starting, stopping, or changing esomeprazole dose
Ketoconazole, Itraconazole	Reduced absorption due to elevated gastric pH	Consider alternative antifungal or use azole that does not require acidic environment
Digoxin	Possible modest increase in digoxin absorption	Monitor serum digoxin levels, especially in patients at risk of toxicity
Tacrolimus	Slight increase in tacrolimus levels (CYP3A4 interaction)	Monitor tacrolimus trough levels
Diazepam	Modestly reduced clearance via CYP2C19 inhibition	Clinical monitoring; dose adjustment rarely needed
Phenytoin	Possible modest increase in phenytoin levels	Monitor phenytoin levels if symptoms of toxicity occur
Mycophenolate mofetil	Reduced exposure to mycophenolic acid	Clinical monitoring; may need dose adjustment in transplant patients
Iron supplements	Reduced iron absorption due to elevated gastric pH	Space administration or use iron formulations that do not require acidic environment

Common Adverse effects

Headache
Abdominal pain
Nausea
Diarrhoea
Constipation
Flatulence
Dry mouth

Serious Adverse effects

Adverse Effect	Clinical Notes
Clostridioides difficile-associated diarrhoea (CDAD)	May occur during or after therapy; discontinue PPI and treat appropriately
Hypomagnesaemia	Risk with prolonged use (>1 year); may cause tetany, seizures, arrhythmias. Discontinuation usually reverses.
Vitamin B12 deficiency	With long-term use (>3 years); monitor and supplement if deficient
Acute interstitial nephritis	Rare; presents with acute kidney injury. Discontinue immediately and refer.
Bone fractures	Increased risk of hip, wrist, and spine fractures with long-term use, especially in elderly
Cutaneous lupus erythematosus / Subacute cutaneous lupus	Rare; discontinue if lupus-like rash develops
Fundic gland polyps	Associated with prolonged use; generally benign
Severe skin reactions (SJS/TEN)	Very rare; immediate discontinuation and hospitalisation required

Monitoring requirements

Baseline:

Clinical assessment of symptoms and alarm features
Hepatic function tests (if hepatic history or planned long-term use)
Consider endoscopy in patients with alarm symptoms before initiating long-term therapy

After initiation/dose change:

Assess symptom response at 4 weeks
If inadequate response to 8-week course: refer for endoscopy

Long-term (if therapy >12 months):

Serum magnesium: every 6–12 months (more frequently if on concurrent diuretics or digoxin)
Serum vitamin B12: annually if on continuous therapy >3 years
Bone mineral density (DEXA): consider in patients with osteoporosis risk factors on prolonged therapy
Periodic reassessment of continued need for PPI therapy

Brands in India

Brand Name	Manufacturer
Nexpro	Torrent Pharmaceuticals
Esoz	Sun Pharmaceutical
Esomac	Cipla
Nexium	AstraZeneca
Sompraz	Sun Pharmaceutical
Raciper	Cadila
Izra	Aristo

Common Fixed-Dose Combinations (FDCs):

Esomeprazole + Domperidone (e.g., Nexpro RD, Esoz D)
Esomeprazole + Levosulpiride

Price range (INR)

Formulation	Approximate Price
Tablet 20 mg (per tablet)	₹5–10
Tablet 40 mg (per tablet)	₹8–15
Injection 40 mg (per vial)	₹50–100
Sachet 20 mg / 40 mg (per sachet)	₹10–20

Regulatory status: Esomeprazole is not individually listed in NLEM 2022 (omeprazole is listed); pricing not currently under NPPA ceiling control for most formulations.

Clinical pearls

Administer correctly — Take esomeprazole 30–60 minutes before meals for optimal acid suppression; food reduces bioavailability.
Do not use indefinitely without indication — Reassess need for PPI therapy at least annually; many patients can be stepped down or discontinued.
Endoscopy before long-term therapy — In patients with alarm features (dysphagia, weight loss, anaemia, recurrent vomiting, GI bleeding), perform endoscopy to rule out malignancy before initiating prolonged PPI therapy.
Clopidogrel interaction — If a PPI is essential in patients on clopidogrel, consider pantoprazole or rabeprazole which have less CYP2C19 inhibition compared to esomeprazole/omeprazole.
Monitor for deficiencies in long-term users — Hypomagnesaemia and B12 deficiency are clinically significant; screen periodically in patients on therapy >1 year.
Esomeprazole vs Omeprazole — Esomeprazole (S-isomer) offers marginally more consistent acid suppression, but clinical superiority over omeprazole in most conditions is minimal. Choice may depend on availability and cost.

Version

RxIndia v1.0 — 01 Jul 2025

Reference

CDSCO product inserts
Indian Pharmacopoeia / NFI
API Textbook of Medicine, 11th Edition
AIIMS Drug Formulary
IAP Guidelines (Paediatric GERD Management)
Indian Society of Gastroenterology Recommendations
NLEM 2022 (omeprazole listed; esomeprazole referenced as therapeutic alternative)
Harrison's Principles of Internal Medicine (supportive reference)
Goodman & Gilman's The Pharmacological Basis of Therapeutics (pharmacology reference)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...